-21.8%
CIFR vs MRNA
-25.6%
+3.8%
-95.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.4% | +1.3% | -2.7% | -1.6% |
| 7D | -9.4% | -13.8% | +4.5% | -7.2% |
| 30D | -27.0% | -17.7% | -9.4% | -25.1% |
| 3M | -59.2% | +14.3% | -73.5% | -61.0% |
| 6M | -65.5% | +336.0% | -401.5% | -80.3% |
| YTD | -56.1% | +575.9% | -632.0% | -80.1% |
| 1Y | -55.7% | +724.4% | -780.0% | -81.8% |
| 3Y | +161.8% | +160.8% | +1.1% | +61.3% |
| All | -21.8% | -25.6% | +3.8% | -30.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling